Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBI-AVM Study
NCT05125471Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cobimetinib in arteriovenous malformation (AVM), sponsored by University of Arkansas. Primary endpoint: Objective Response Rate at 1 year. Started Jul 2022; status: completed.
02
Drugs
cobimetinib
03
Conditions
arteriovenous malformation (AVM)
Beyond the preview
Go deeper on NCT05125471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125471.